CN108707151B - 嘧啶并-哒嗪酮化合物及其用途 - Google Patents

嘧啶并-哒嗪酮化合物及其用途 Download PDF

Info

Publication number
CN108707151B
CN108707151B CN201810492306.1A CN201810492306A CN108707151B CN 108707151 B CN108707151 B CN 108707151B CN 201810492306 A CN201810492306 A CN 201810492306A CN 108707151 B CN108707151 B CN 108707151B
Authority
CN
China
Prior art keywords
pyridazin
amino
phenyl
oxo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810492306.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108707151A (zh
Inventor
阿拉纳巴堪·文卡特桑
罗格·阿斯特伯里·史密斯
苏布拉马尼亚·霍沙哈利
维贾伊·波特卢里
苏尼尔·库马·帕尼格拉希
维什努·巴塞蒂
卡鲁纳斯里·昆图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liberty Biology Co.,Ltd.
Original Assignee
Asana Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences LLC filed Critical Asana Biosciences LLC
Publication of CN108707151A publication Critical patent/CN108707151A/zh
Application granted granted Critical
Publication of CN108707151B publication Critical patent/CN108707151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201810492306.1A 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途 Active CN108707151B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
US61/526,525 2011-08-23
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof
CN201280051788.8A CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051788.8A Division CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Publications (2)

Publication Number Publication Date
CN108707151A CN108707151A (zh) 2018-10-26
CN108707151B true CN108707151B (zh) 2022-06-03

Family

ID=46829884

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810492306.1A Active CN108707151B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途
CN201280051788.8A Active CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280051788.8A Active CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Country Status (14)

Country Link
US (5) US8729079B2 (enExample)
EP (4) EP3392252B1 (enExample)
JP (1) JP5993010B2 (enExample)
CN (2) CN108707151B (enExample)
BR (1) BR112014003981A2 (enExample)
CA (1) CA2846187A1 (enExample)
DK (2) DK2748166T3 (enExample)
ES (2) ES2969977T3 (enExample)
FI (1) FI3392252T3 (enExample)
HU (1) HUE065564T2 (enExample)
IL (1) IL231082A (enExample)
MX (1) MX361458B (enExample)
PL (1) PL2748166T3 (enExample)
WO (1) WO2013028818A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003981A2 (pt) * 2011-08-23 2017-03-07 Endo Pharmaceuticals Inc compostos de pirimido-piridazinona e seu uso
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN110809471A (zh) 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
CN114174298B (zh) * 2019-08-14 2023-08-01 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
US20250171448A1 (en) 2022-02-23 2025-05-29 Teva Pharmaceuticals International Gmbh Solid state forms of gusacitinib
WO2023192989A2 (en) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor
IL326153A (en) 2023-07-27 2026-03-01 Libertas Bio Inc Solid state forms of GUSACITINIB

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764598A (en) * 1969-09-24 1973-10-09 Takeda Chemical Industries Ltd Pyrimidopyridazine derivatives
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2010038060A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2011053861A1 (en) * 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (enExample) 1972-07-29 1974-04-27
JPS50101387A (enExample) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
ID28376A (id) 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
JP4977940B2 (ja) * 2000-09-22 2012-07-18 エム・エス・ディー・オス・ベー・フェー 二環式ヘテロ芳香族化合物
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US8575342B2 (en) 2004-09-30 2013-11-05 Tibotech Pharmaceuticals Ltd. HIV inhibiting 5-heterocyclyl pyrimidines
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
EP1874304B1 (en) 2005-04-29 2009-07-15 Janssen Pharmaceutica N.V. Benzotriazole derivatives as cannabinoid receptor antagonists
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
BRPI0808772A2 (pt) 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
EA022417B1 (ru) 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
BR112014003981A2 (pt) * 2011-08-23 2017-03-07 Endo Pharmaceuticals Inc compostos de pirimido-piridazinona e seu uso
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
CN110809471A (zh) * 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764598A (en) * 1969-09-24 1973-10-09 Takeda Chemical Industries Ltd Pyrimidopyridazine derivatives
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2010038060A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2011053861A1 (en) * 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Also Published As

Publication number Publication date
US20200190095A1 (en) 2020-06-18
DK2748166T3 (en) 2018-10-29
EP2748166B1 (en) 2018-07-11
US20140221315A1 (en) 2014-08-07
PL2748166T3 (pl) 2019-05-31
JP2014524475A (ja) 2014-09-22
US9382277B2 (en) 2016-07-05
EP3404029A3 (en) 2018-12-12
JP5993010B2 (ja) 2016-09-14
ES2969977T3 (es) 2024-05-23
IL231082A0 (en) 2014-03-31
DK3392252T3 (da) 2024-01-08
US20190092779A1 (en) 2019-03-28
ES2690971T3 (es) 2018-11-23
CN108707151A (zh) 2018-10-26
EP3392252B1 (en) 2023-10-04
US20160257691A1 (en) 2016-09-08
EP2748166A1 (en) 2014-07-02
US8729079B2 (en) 2014-05-20
US10647720B2 (en) 2020-05-12
EP3392252A1 (en) 2018-10-24
EP4327886A3 (en) 2024-05-22
MX2014002112A (es) 2014-09-25
MX361458B (es) 2018-12-06
HUE065564T2 (hu) 2024-06-28
WO2013028818A8 (en) 2013-09-19
WO2013028818A1 (en) 2013-02-28
US20130053346A1 (en) 2013-02-28
CN103974955A (zh) 2014-08-06
FI3392252T3 (fi) 2024-01-08
BR112014003981A2 (pt) 2017-03-07
IL231082A (en) 2016-09-29
US10183944B2 (en) 2019-01-22
EP4327886A2 (en) 2024-02-28
CA2846187A1 (en) 2013-02-28
CN103974955B (zh) 2018-06-19
EP3404029A2 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
CN103974955B (zh) 嘧啶并-哒嗪酮化合物及其用途
CN1871240B (zh) 吡咯并嘧啶酮衍生物
SG176461A1 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20080171769A1 (en) Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2999539T3 (en) 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis
KR20200034781A (ko) 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 유사체
CN102307875A (zh) 吡咯并嘧啶基axl激酶抑制剂
KR20010085824A (ko) 단백질 키나아제 억제제로서의 피롤로피리미딘
US20240166617A1 (en) Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
TW201319067A (zh) 三唑并吡啶化合物
WO2018187294A1 (en) Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN119790043A (zh) 三环类化合物及其应用
US9290503B2 (en) Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CN111961035B (zh) 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
HK40107186A (en) Pyrimido- pyridazinone compounds and use thereof
HK40000773A (en) Pyrimido-pyridazinone compounds and methods and use thereof
HK1262920A1 (en) Pyrimido- pyridazinone compounds and use thereof
HK1262920B (en) Pyrimido- pyridazinone compounds and use thereof
KR20220133874A (ko) 매크로사이클릭 화합물
TW202140474A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN118702697A (zh) 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN120365268A (zh) 一种靶向hpk1的疏水标签化合物、药物组合物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220725

Address after: new jersey

Patentee after: ABS development 1 Co.,Ltd.

Address before: new jersey

Patentee before: Asana BioSciences, LLC

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: new jersey

Patentee after: Liberty Biology Co.,Ltd.

Address before: new jersey

Patentee before: ABS development 1 Co.,Ltd.